Myriad Genetics Inc
MYGN6.550USD
-0.010-0.15%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
609.80MMarket Cap
LossP/E TTM
More Details of Myriad Genetics Inc Company
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Myriad Genetics Inc Info
Ticker SymbolMYGN
Company nameMyriad Genetics Inc
IPO dateOct 06, 1995
CEORaha (Samraat S)
Number of employees2700
Security typeOrdinary Share
Fiscal year-endOct 06
Address322 North 2200 West
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84116
Phone18015843600
Websitehttps://myriad.com/
Ticker SymbolMYGN
IPO dateOct 06, 1995
CEORaha (Samraat S)
Company Executives of Myriad Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Mr. Benjamin Richard (Ben) Wheeler
Mr. Benjamin Richard (Ben) Wheeler
Chief Financial Officer
Chief Financial Officer
92.65K
-2.69%
Dr. Dale Muzzey
Dr. Dale Muzzey
Chief Scientific Officer
Chief Scientific Officer
45.88K
-46.96%
Ms. S. Louise Phanstiel, CPA
Ms. S. Louise Phanstiel, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matt Scalo
Mr. Matt Scalo
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Donnelly
Mr. Brian Donnelly
Chief Commercial Officer
Chief Commercial Officer
397.53K
--
Mr. Mark S. Verratti
Mr. Mark S. Verratti
Chief Operating Officer and Chief Commercial Officer
Chief Operating Officer and Chief Commercial Officer
220.57K
-0.49%
Dr. Lee Nisley Newcomer, M.D.
Dr. Lee Nisley Newcomer, M.D.
Independent Director
Independent Director
132.14K
+60.47%
Ms. Margaret (Maggie) Ancona
Ms. Margaret (Maggie) Ancona
Senior Vice President, Chief of Staff
Senior Vice President, Chief of Staff
127.73K
-0.74%
Ms. Rashmi Kumar
Ms. Rashmi Kumar
Independent Director
Independent Director
127.19K
+64.34%
Ms. Shereen Solaiman
Ms. Shereen Solaiman
Chief People Officer
Chief People Officer
110.96K
+98.89%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
By RegionUSD
Name
Revenue
Proportion
United States
198.20M
93.01%
Rest of world
14.90M
6.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Hereditary Cancer
96.30M
45.19%
Prenatal
47.60M
22.34%
Pharmacogenomics
37.80M
17.74%
Tumor Profiling
31.40M
14.73%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
Other
62.09%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.22%
The Vanguard Group, Inc.
8.34%
State Street Investment Management (US)
5.34%
Millennium Management LLC
5.09%
Glenview Capital Management, LLC
4.92%
Other
62.09%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.68%
Investment Advisor/Hedge Fund
27.22%
Hedge Fund
25.48%
Research Firm
5.93%
Individual Investor
3.28%
Pension Fund
1.73%
Bank and Trust
0.41%
Family Office
0.24%
Sovereign Wealth Fund
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
518
92.00M
98.69%
-11.12M
2025Q2
518
100.80M
108.34%
-1.85M
2025Q1
527
99.14M
107.57%
-4.54M
2024Q4
516
96.89M
106.12%
-1.41M
2024Q3
505
95.02M
104.61%
-5.50M
2024Q2
486
96.79M
106.52%
-6.22M
2024Q1
460
98.19M
108.68%
+613.48K
2023Q4
464
93.46M
105.77%
+2.70M
2023Q3
471
86.01M
104.78%
-3.73M
2023Q2
480
84.60M
103.32%
-6.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.43M
14.43%
-416.99K
-3.01%
Jun 30, 2025
The Vanguard Group, Inc.
9.15M
9.83%
-1.47M
-13.83%
Jun 30, 2025
State Street Investment Management (US)
4.81M
5.17%
-458.84K
-8.71%
Jun 30, 2025
Millennium Management LLC
4.92M
5.29%
+855.19K
+21.01%
Jun 30, 2025
Glenview Capital Management, LLC
4.59M
4.93%
+687.86K
+17.64%
Jun 30, 2025
D. E. Shaw & Co., L.P.
4.51M
4.85%
+1.99M
+78.84%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.37M
3.63%
+1.97M
+140.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.22M
2.39%
-7.80K
-0.35%
Jun 30, 2025
Camber Capital Management LP
2.00M
2.15%
-350.00K
-14.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Genomics & Biotechnology ETF
0.8%
Invesco NASDAQ Future Gen 200 ETF
0.68%
Federated Hermes MDT Small Cap Core ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.46%
State Street SPDR S&P Biotech ETF
0.24%
Strategas Global Policy Opportunities ETF
0.22%
Inspire Small/Mid Cap ESG ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Quality Factor ETF
0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
View more
Global X Genomics & Biotechnology ETF
Proportion0.8%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.68%
Federated Hermes MDT Small Cap Core ETF
Proportion0.5%
Invesco S&P SmallCap Health Care ETF
Proportion0.46%
State Street SPDR S&P Biotech ETF
Proportion0.24%
Strategas Global Policy Opportunities ETF
Proportion0.22%
Inspire Small/Mid Cap ESG ETF
Proportion0.22%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.14%
Vanguard US Quality Factor ETF
Proportion0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.12%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Myriad Genetics Inc?
The top five shareholders of Myriad Genetics Inc are:
BlackRock Institutional Trust Company, N.A. holds 13.43M shares, accounting for 14.43% of the total shares.
The Vanguard Group, Inc. holds 9.15M shares, accounting for 9.83% of the total shares.
State Street Investment Management (US) holds 4.81M shares, accounting for 5.17% of the total shares.
Millennium Management LLC holds 4.92M shares, accounting for 5.29% of the total shares.
Glenview Capital Management, LLC holds 4.59M shares, accounting for 4.93% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.43M shares, accounting for 14.43% of the total shares.
The Vanguard Group, Inc. holds 9.15M shares, accounting for 9.83% of the total shares.
State Street Investment Management (US) holds 4.81M shares, accounting for 5.17% of the total shares.
Millennium Management LLC holds 4.92M shares, accounting for 5.29% of the total shares.
Glenview Capital Management, LLC holds 4.59M shares, accounting for 4.93% of the total shares.
What are the top three shareholder types of Myriad Genetics Inc?
The top three shareholder types of Myriad Genetics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of Myriad Genetics Inc (MYGN)?
As of 2025Q3, 518 institutions hold shares of Myriad Genetics Inc, with a combined market value of approximately 92.00M, accounting for 98.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.65%.
What is the biggest source of revenue for Myriad Genetics Inc?
In FY2025Q2, the Hereditary Cancer business generated the highest revenue for Myriad Genetics Inc, amounting to 96.30M and accounting for 45.19% of total revenue.
